Neuroimaging in Lewy body dementia

Journal of Neurology
Tayyabah YousafMarios Politis

Abstract

Lewy body dementia (DLB) is a common form of cognitive impairment, accounting for 30% of dementia cases in ages over 65 years. Early diagnosis of DLB has been challenging; particularly in the context of differentiation with Parkinson's disease dementia and other forms of dementias, such as Alzheimer's disease and rapidly progressive dementias. Current practice involves the use of [123I]FP-CIT-SPECT, [18F]FDG PET and [123I]MIBG molecular imaging to support diagnostic procedures. Structural imaging techniques have an essential role for excluding structural causes, which could lead to a DLB-like phenotype, as well as aiding differential diagnosis through illustrating disease-specific patterns of atrophy. Novel PET molecular imaging modalities, such as amyloid and tau imaging, may provide further insights into DLB pathophysiology and may aid in early diagnosis. A multimodal approach, through combining various established techniques and possibly using novel radioligands, might further aid towards an in-depth understanding of this highly disabling disease. In this review, we will provide an overview of neuroimaging applications in patients with DLB.

References

May 20, 2000·Annals of the New York Academy of Sciences·C BallardR A Kenny
Oct 25, 2000·International Journal of Geriatric Psychiatry·R BarberJ T O'Brien
Apr 27, 2002·European Journal of Nuclear Medicine and Molecular Imaging·Sean J CollobyJohn T O'Brien
Dec 25, 2002·Neurobiology of Aging·Heiko BraakEva Braak
Jul 10, 2003·Lancet Neurology·John T O'BrienSteven T DeKosky
Apr 9, 2004·Proceedings of the National Academy of Sciences of the United States of America·Michael D GreiciusVinod Menon
Apr 16, 2005·Dementia and Geriatric Cognitive Disorders·Soichiro ShimizuKimihiko Abe
Sep 27, 2006·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Emma J BurtonJohn T O'Brien
Feb 3, 2007·Brain : a Journal of Neurology·Jennifer L WhitwellClifford R Jack
Mar 14, 2007·Journal of Neurology, Neurosurgery, and Psychiatry·Zuzana WalkerCornelius L E Katona
May 16, 2007·Neurology·C C RoweV L Villemagne
Jun 1, 2007·Nuclear Medicine Communications·Paul M Kemp, Clive Holmes
Jun 2, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Murat EmreBruno Dubois
Nov 29, 2007·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·C-C ChangC-H Lee
May 15, 2008·Dementia and Geriatric Cognitive Disorders·Robert PerneczkyPeter Häussermann
Jul 26, 2008·Journal of Neurology, Neurosurgery, and Psychiatry·P EdisonD J Brooks
Sep 17, 2008·Neurology·S N GompertsK A Johnson
Jan 2, 2009·The British Journal of Psychiatry : the Journal of Mental Science·John T O'BrienUNKNOWN DLB Study Group
Jan 24, 2009·Neurobiology of Disease·Walter MaetzlerDaniela Berg
Jul 2, 2009·Movement Disorders : Official Journal of the Movement Disorder Society·Cristina Sanchez-CastanedaCarme Junque
Jul 7, 2009·European Journal of Pharmacology·Michelle T Fodero-TavolettiVictor L Villemagne
Sep 18, 2009·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Seok Ming LimChristopher C Rowe
Oct 31, 2009·Movement Disorders : Official Journal of the Movement Disorder Society·Rodney W H Walker, Zuzana Walker
Nov 13, 2009·Movement Disorders : Official Journal of the Movement Disorder Society·Ji E LeePhil Hyu Lee
Feb 23, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Cristina Sanchez-CastanedaCarme Junque

❮ Previous
Next ❯

Citations

Dec 23, 2019·Alzheimer's Research & Therapy·Anne BotzungFrédéric Blanc
Jun 20, 2019·Current Neurology and Neuroscience Reports·Stéphane PrangeStéphane Thobois
Oct 28, 2020·Annals of Clinical and Translational Neurology·Nicola SpotornoDavid J Irwin
Oct 15, 2020·International Journal of Molecular Sciences·Maria RicciOrazio Schillaci
Jul 3, 2021·Behavioral Sciences·Ángela Milán-TomásMaría Cruz Rodríguez-Oroz
Jun 16, 2021·Neurobiology of Aging·Daniel FerreiraKejal Kantarci
Jul 20, 2021·Curēus·Abhishikta Saha, Dipanjan Banerjee
Sep 18, 2021·Molecular Medicine·Sanne K MelesKlaus L Leenders

❮ Previous
Next ❯

Methods Mentioned

BETA
imaging techniques

Software Mentioned

fMRI
rs

Related Concepts

Related Feeds

Alzheimer's Disease: Early Markers

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive and behavioral decline. Targeting markers in the earliest stages of the disease may mitigate the progression of AD. This feed focuses on early diagnosis and markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Related Papers

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
Lisa MosconiMony J de Leon
European Radiology
Pervinder BhogalHans Rolf Jäger
Clinical Nuclear Medicine
Charles MarcusRathan M Subramaniam
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
Ilya M Nasrallah, David A Wolk
© 2022 Meta ULC. All rights reserved